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Diabetic retinopathy (DR) is a microvascular complication associated with chronic exposure to hyperglycemia and is a major cause
of blindness worldwide. Although clinical assessment and retinal autopsy of diabetic patients provide information on the features
and progression of DR, its underlying pathophysiological mechanism cannot be deduced. In order to have a better understanding
of the development of DR at the molecular and cellular levels, a variety of animal models have been developed. They include
pharmacological induction of hyperglycemia and spontaneous diabetic rodents as well as models of angiogenesis without diabetes
(to compensate for the absence of proliferative DR symptoms). In this review, we summarize the existing protocols to induce
diabetes using STZ. We also describe and compare the pathological presentations, in both morphological and functional aspects,
of the currently available DR animal models. The advantages and disadvantages of using different animals, ranging from zebrafish,
rodents to other higher-order mammals, are also discussed. Until now, there is no single model that displays all the clinical features
of DR as seen in human. Yet, with the understanding of the pathological findings in these animal models, researchers can select the
most suitable models for mechanistic studies or drug screening.
1. Introduction
Diabetic retinopathy (DR) is a one of the most common
microvascular complications of diabetes. In 2012, there are
more than 371 million people suffering from diabetes, and
it is being projected that the number of diabetic patients
will reach 550 million in 2030 (http://www.eatlas.idf.org/;
assessed 29-Nov-2012).Diabetes can be generally divided into
two types: type 1 (insulin dependent) and type 2 (insulin
independent), although patients of both types will have
hyperglycemia. A study reported that about one-third of the
diabetic patients have signs of DR and about one-tenth of
them even have vision-threatening retinopathy [1]. Nearly
60% and 35% of DR patients progress to proliferative DR and
severe vision loss in 10 years, respectively [2].
Clinically, DR can be classified into nonproliferative
(NPDR) and proliferative (PDR) [3]. NPDR can be further
graded into mild, moderate, and severe and is characterized
by the presence of microaneurysms, hemorrhages, hard
exudates (liquid deposits), cotton wool spots, intraretinal
microvascular abnormalities, venous beading, and loop for-
mation. NPDR may develop into PDR, where hallmarks of
neovascularization of the retina and vitreous hemorrhage are
found. Vision loss can be resulted from retinal detachment if
patients are left untreated. Moreover, maculopathy, including
macular edema and ischemia, can occur at any stage of DR; it
accounts for the majority of the blindness due to DR. In fact,
the growing number of diabetic patients and a longer life span
in the aging population imply an increase in patients suffering
from DR, which not only affects the quality of life of the
individuals and their families but also increases the medical
and economical burden to the society. As a consequence,
effective therapy is urgently needed.
In order to develop effective drugs, detailed understand-
ing of the pathophysiological progression of DR is required.
Over half a century ago, histological studies have been
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performed in postmortem retinas of diabetic patients. In
retinal vessels and capillaries, selective endothelial andmural
cells loss, presence of mural cell ghosts, endothelial clusters,
acellularity, and microaneurysms were found to be increased
in diabetic patients [4, 5]. Basement membrane thickening,
presence of hemorrhage in the inner nuclear layer (INL), and
outer plexiform layer (OPL) as well as eosinophilic exudates
in the OPL were also reported [5].
Nowadays, immunological studies evidenced an
increased glial fibrillary acidic protein (GFAP) expression
in the Mu¨ller cell processes throughout the inner and
outer diabetic retina, suggesting that these cells were
hypertrophied [6]. There was also increased apoptosis in
diabetic retina [7]. Abu El-Asrar et al. [8] further showed
that proapoptotic molecules were expressed in ganglion
cells, together with the activation of glial cells, which
expressed several antiapoptotic molecules. Elevated vascular
endothelial growth factor (VEGF) immunoreactivity was
found in retinal blood vessels in diabetic humans with
preproliferative or no retinopathy, further consolidated the
role of VEGF in angiogenesis and vascular permeability [9].
Alternation in other factors, including somatostatin [10],
cortistatin [11], 𝛼A and 𝛼B-crystallins, advanced glycation
end products (AGEs), and receptor for AGE (RAGE) [12] as
well as apolipoprotein A1 (ApoA1) [13], were also observed
in the postmortem tissues. Somatostatin and cortistatin,
which are neuropeptides with a very similar structure,
were both downregulated in diabetic retinas, and their
expression levels are inversely correlated with glial activation
and apoptosis. On the other hand, upregulations of 𝛼A-,
𝛼B-crystallin, AGE, RAGE, and ApoA1 in the diabetic retinal
tissue were reported. These morphological studies provide a
better picture, yet without the mechanistic pathway, of the
pathogenesis of DR at a cellular level. Moreover, advanced
technologies further allow us to study the mRNA or protein
expressions of various chemokines [14–17], cytokines [15–
18], inflammatory markers [16, 19, 20], angiogenic factors
[16, 17, 19–21], and other factors [19, 22, 23] in aqueous
humor, serum, or urine from diabetic patients, thereby
predicting the pathological pathways of DR. With the
aid of the sophisticated computerized equipments and
technologies, clinicians would even be able to monitor or
predict the progression structural lesion [24–29] as well as
functional defects [30, 31] in live patients with DR.
Although a lot of important information or clues on the
development of DR can be obtained from human studies, the
mechanisms of DR development still cannot be elucidated.
Emergence of animalmodels, therefore, not only enables us to
have a more comprehensive understanding of the etiology of
DRat amolecular level in a controlledmanner, but also fulfills
the need for drug screening tools.With thesemodels, wemay
even be able to discover the early markers for DR in the body
fluids from diabetic patients.This not only allows a faster and
more convenient screening but also serves as an alarm for
diabetic patients before the presence of cellular or functional
lesion. Until now, many studies on the pathogenesis of DR
have been carried out in animal models. A cascade of events,
including oxidative stress, inflammation, protein kinase C
(PKC) activation, accumulation of AGE and sorbitol, and
upregulation of rennin-angiotensin system (RAS) and VEGF,
contribute to retinal vascular endothelial dysfunction as
a result of hyperglycemia [3]. Based on the mechanistic
studies, drugs targeting different molecules in the cascade
are being developed. In order to evaluate the effect of the
drug properly, reliable and appropriate animal models are
required. Throughout the years, many animal models of DR
have been developed; however, none of them can mimic the
entire pathophysiological progression as observed in human.
While most animal models only show the early symptoms
of DR, some show the late stage proliferative angiogenesis.
Researchers have to select an appropriate model or models
which can compensate each other in order to address their
research questions. In this review, we focus on the animal
models of DR that researchers have used, briefly describe
how the models were generated, highlight the morphological
and functional changes in the retina, and finally discuss the
strengths and weaknesses of each model.
2. Animal Models
2.1.MouseModels ofDR. In general,mice have been routinely
used in many in vivo studies since they are small in size
and therefore easy to handle and inexpensive to house. They
also have relatively short life span that allows a shorter
experimental turnover time. Indeed, mechanistic studies of
DR have been carried out extensively in mice as these models
share similar symptoms of early DR as in human. More
importantly, the availability of a collection of transgenic
and knockout mice allows researchers to study the role of
particular genes, which may even be cell type specific, in
the development and pathophysiological progression of DR.
There are three main types of mouse models to study DR;
the first two involve mice with hyperglycemia development
either via pharmacological induction or inbreeding of mice
with endogenous mutation while the third type focuses
on pathological angiogenesis found in transgenic animals
or induced by experimental procedures, in mice without
diabetes.
2.1.1. Pharmacologically Induced Mouse Models of DR. Type 1
diabetes can be induced in mice by injection of chemicals,
including streptozotocin (STZ) and alloxan, both of which
are toxic to and therefore destroy the 𝛽-cells in the pancreatic
islets. Hyperglycemia can also be induced in mice by feeding
with galactose.
STZ-induced mice have been routinely used as a DR
model in a lot of mechanistic studies and therapeutic drug
testing for a long period of time owing to the abundant
reports on the phenotypes. Depending on the injection
dosage, the onset of diabetes can be achieved within a few
days after injection in the wild-type animals, making it a pop-
ular diabetic model. Nevertheless, there are many variations
in the injection protocol in terms of dosage, route of injection,
and with or without insulin compensation that are usually
based on the practice in individual laboratories; nonetheless,
all mice end up with hyperglycemia in 1 to 4 weeks after STZ
injection. For an easy reference, a summary of DR studies
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using STZ-induced mice in the past five years is presented
in Table 1. This table aims to provide the researchers with a
general idea of the appropriate dosage or injection method
in mice of different age and/or with genetic background.
Amongst these methods, intraperitoneal injection of single
high-dose injection of 150mg/kg and multiple low doses of
50mg/kg for 5 consecutive days to C57Bl/6 mice without
insulin compensation are the standard protocols recom-
mended by the Animal Models of Diabetic Complications
Consortium (http://www.diacomp.org/; accessed on 9-Dec-
2012). In the STZ-induced diabetic mice, transient astrocyte
activation [32] as well as increased astrocyte number [33] was
observed at 4 to 5 weeks of hyperglycemia. GFAP upregula-
tion in glial cells and reactive gliosis were also evidenced at
the same time [33]. Retinal ganglion cells (RGCs) are reduced
starting from6weeks [34, 35] while thinning of INL andONL
were observed at 10 weeks of hyperglycemia [35]. Apoptosis
of RGCs and vascular cells can be identified at 6 weeks
[35] and 6 months [32] of hyperglycemia, respectively. Yet,
some studies showed that there is no significant in ganglion
cell death even after a long time, up to 9 to 10 months of
hyperglycemia [36–39]. Increased leukocyte number [40],
together with leukostasis [38], was reported at 8 weeks
of hyperglycemia. For vascular pathogenesis, upregulation
of vascular permeability was being observed as early as 8
days of hyperglycemia [41], resulting in vessel leakage at 2
months [42]. After 17 weeks of hyperglycemia, thickening
of capillary basal lamina [43] and neovascularization [44]
were reported. Acellular capillaries and pericyte ghosts were
found in retina in mice after 6 to 9 [32, 37] months of
hyperglycemia. Decreased retinal arteriolar and venular RBC
velocities, retinal arteriolar and venular blood flow rates,
and arterial velocity were observed in mice after 4 weeks of
hyperglycemia [45–47]. Although decreased arteriolar and
venular diameters were also reported in mice after 4 weeks of
hyperglycemia [48], it is controversial in other studies. Func-
tional defects were described in some electroretinography
(ERG) studies including decreasedOP3 andΣOPs, prolonged
implicit time of OP2-3 at 4 weeks of hyperglycemia [49, 50];
decreased a-waves and b-waves at 6months of hyperglycemia
[37]; and decreased pattern ERG amplitude at 7 weeks of
hyperglycemia [51]. The variations in the above observations
may be due to difference in mouse strains [52], STZ dosage,
or observation time points. Moreover, individual animals
may be resistant to STZ and fail in hyperglycemia induction;
therefore, it is essential for the experimenters to confirm the
blood glucose level of the animals and exclude those without
hyperglycemia development.
On the other hand, alloxan is less commonly used in
mice, which may be due to the absence of the inducible
cellular and vascular lesions associated with hyperglycemia.
Morphologically, the dendrites of microglial cells were found
to be shortened without any ganglion cell apoptosis after 3
months of hyperglycemia [128]. At the same time, vessel dif-
fusion and density of the retinal capillary network remained
unchanged [128]. Functional abnormalities, however, were
being reported in ERG, in which b-wave amplitude [129,
130] and b/a wave amplitude ratio [128] were found to
be decreased at 3 weeks and 3 months of hyperglycemia,
respectively. Nevertheless, cellular and vascular lesions are
possibly detectable after a longer period of hyperglycemia as
suggested by the presence of functional defects in this model.
Feeding with galactose is another method to induce
hyperglycemia. Here, the blood aldohexose concentration
is elevated in the animal without affecting other metabolic
abnormalities, such as alterations in concentrations of
insulin, glucose, fatty acids, and amino acids. This allows
the researchers to study the consequential retinal compli-
cations solely due to the elevation of hexose concentration.
Galactose-fedmice have a longer life span than other diabetic
models; therefore, an extended monitoring period of up to
26 months can be allowed [131–133]. Endothelial cell loss
and increased acellular capillaries were observed starting
from 15 months of hyperglycemia. For a further 6 months
of hyperglycemia, other morphological lesions including the
presence of pericyte ghosts, saccular microaneurysms as
well as basement membrane thickening of retinal capillaries
were also evidenced [131–133]. Amongst the mouse models
currently available, the animals in this model have the least
mortality at around 2 years old of age, which allows a
longer period of hyperglycemia, and therefore phenotypes
associated with increment of hexose concentration can be
targeted. Researchers should be aware that it takes a relatively
longer period of time to develop retinopathy in these mice,
which in turn leads to a higher cost.
2.1.2. Diabetic Mouse Models Carrying Endogenous Mutation.
Apart from injection or intake of chemicals, spontaneous
hyperglycemia can be found in mice carrying endogenous
mutation. By inbreeding the mutated mice with the wild-
type animals, researchers can further expand the colonies and
use them as mouse models for diabetes studies. Although
breeding is a time-consuming process, further manipula-
tions, such as injections and feeding with specialized chow,
are avoided. Retinopathies in terms of morphological and
functional lesions have been observed in a few type 1 and
type 2 diabetic models, including Ins2Akita, nonobese diabetic
(NOD), db/db, and KKAy mice. In these animals, onset of
hyperglycemia takes place spontaneously as a result of the
presence of the transgene or mutation; a relatively consistent
phenotype as well as a higher success rate in induction of
hyperglycemia can be obtained.
The Ins2Akita mice represent one of the spontaneous type
1 diabetic models. These mice carry a point mutation in
the insulin2 gene, which causes a conformational change in
the protein that accumulates in the pancreatic 𝛽-cells, and
ultimately leads to cell death. Retinopathy in heterozygous
Ins2Akita mice is well characterized in a few studies. Cellular
lesions, such as reactive microglia, are evidenced as early as
8 weeks of diabetes [134]. By 12 weeks of onset of hyper-
glycemia, immunological studies showed abnormal swelling
in somas, axons, and dendrites of RGCs, and the number
of these cells was reduced in the peripheral region; while
more dendritic terminals, increased total dendrite length,
and greater dendritic density were observed in the ON-type
RGCs [135]. It has been reported that the number of RGCs
was significantly reduced in the peripheral regions after 22
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weeks of hyperglycemia [135]; yet, another study showed that
there was no ganglion cell death in these mice even up to
10 months of hyperglycemia [39]. Morphological change in
astrocyteswas also observedwhere they had short projections
and became in less contact with the vessels [134]. Moreover,
the IPL and INL became thinner, which may be due to the
decrease of the cholinergic and dopaminergic amacrine cells
as evidenced in retina after 6 months of hyperglycemia [136].
Vascular lesions such as increased of leukocyte number are
already found in mice upon 8 weeks of hyperglycemia and
retinal vascular permeability was increased in 12 weeks of
hyperglycemia.The presence of acellular capillaries [134] and
neovascularization [137] were described after 8 to 9 months
of hyperglycemia. Abnormal vascular functions were also
reported in a study which showed that the arteriolar and
venular RBC velocity, shear rate, and retinal blood flow rate
were significantly decreased in the diabetic animals with 26
weeks of hyperglycemia [138]. A decrease of a- and b-wave
amplitudes in the ERG after 8 month indicates functional
problem associated with the cellular defects or degeneration
[137]. Although the diabetic animals have an average life span
of 305 days, they provide a stable induction of hyperglycemia
while projecting the early and some of the late DR symptoms
in human. Thus, this model could be very useful in drug
screening, and it has received more attention in the field of
DR.
The NOD mice are another model of type 1 diabetes,
in which pancreatic 𝛽-cells were destroyed via an autoim-
mune process by the CD4+ and CD8+ cells. The onset of
hyperglycemia in these animals is 12 weeks of age, and the
frequency of having hyperglycemia at the age of 30 weeks old
is about 80% in female and less than 20% inmale [139].Owing
to the low induction rate and inconsistency in the male mice,
female NODmice were commonly used. Using transmission
electronmicroscopy, ultrastructural changes including apop-
tosis of pericytes, endothelial cells, and RGCs, perivascular
edema, and retinal capillary basement membrane thickening
were reported as early as 4 weeks of hyperglycemia, and these
retinopathogeneses became more obvious after 12 weeks of
hyperglycemia [140]. At about 4 months of hyperglycemia,
vascular abnormalities were described in the NOD mice.
Vasoconstriction or degeneration was observed in some
of the major vessels, together with the presence of poorly
definedmicrovessels and disordered focal proliferation of the
new vessels [141]. The presence of these vascular pathologies
and the etiology of the development of type 1 diabetes in the
NOD mice are relatively similar to those of human, making
this model unique. However, there is a big variation in the
time of onset of diabetes; frequent and regular monitoring
of the blood glucose levels is therefore required. More
importantly, since female animals were used in these studies,
estrogen, which plays a role in regulation of metabolism
[142], may have a protective function in DR. This further
complicates the mechanistic studies or contributes unknown
effects in drug screening, thereby affecting the accuracy.
The db/db mice spontaneously develop type 2 diabetes
owing to the deficiency in the leptin receptor. Hyperglycemia
and obesity were observed in the homozygous mice at 4 to
8 weeks old [143]. Reduction of RGC number and thickness
of the central total retina, INL, and photoreceptor layers were
identified in the histological sections of mice after 6 weeks of
hyperglycemia [144]. After 18 weeks [145] and 13 months of
onset of hyperglycemia [146], pericyte loss and glial reacti-
vation were reported, respectively. Vascular lesions including
capillary basement membrane thickening [147], the presence
of acellular capillaries [145], increased vessel density in the
INL, and vessel leakage [146] were observed in the diabetic
retina. Compared with other mouse models, the reported
glial reactivation and vessel leakage occurred relatively late in
db/db mice, which could be explained by a relative late time
point chosen in a long-term study [146]. The use of db/db
mice to study DR is not very popular, potentially due to a
low birth rate resulting from the unsatisfactory mating per-
formance in the male homozygotes and failure to reproduce
in the female homozygotes (http://jaxmice.jax.org/; accessed
on 15-Dec-2012).
KKAy mouse is a combined model made by the intro-
duction of the yellow obese gene, Ay, into the KK mouse, in
which moderate diabetic traits are thought to be inherited
by polygenes. These mice spontaneously develop diabetic
characteristics, such as hyperglycemia, hyperinsulinemia,
and obesity, at around 6 to 8 weeks of age, but revert to
normal at the age of 40 weeks [148]. Of the limited DR
studies using this mouse model, increased apoptosis of the
retinal neuronal cells was found in the RGC layer and the
INL in mice after 4 weeks and 3 months of hyperglycemia,
respectively. Capillary basement membrane thickening was
also observed in ultrastructural study [149]. Owing to the
limited retinopathologic findings and the uncertain etiology
of this model, this model is not popularly used in DR studies.
2.1.3. Mouse Models of Proliferative Retinopathy. In order to
compensate for the lack of proliferative pathogenesis in the
retinal vasculature in most of the above diabetic mouse mod-
els, researchers developed a number of nondiabetic models,
which allow them to specifically target neovascularization
in the ocular region. When using these models, however,
researchers should be aware of the fact that the etiology of
the progression of vascular abnormalities is different owing
to the absence of classical systemic characteristics as seen
in diabetes. Proliferative retinopathy can be achieved mainly
from two approaches: the first one is via introduction of
ischemia to the eyes, such as oxygen-induced retinopathy
(OIR) and retinal occlusion [150]; the second one is by direct
injection or genetically induction of the angiogenic factor,
VEGF, into the ocular region.
OIR originally is an animal model of retinopathy of
prematurity in newborns. Owing to the presence of neo-
vascularization, this model is also adapted for studying the
angiogenesis as seen in proliferative DR [150]. In brief,
postnatal day 7 (P7) neonatal mice were put into a 75%
oxygen chamber for five days and then returned to room air
[151, 152]. Vessel loss in the central area of retina, which is
associated with hypoxic challenged, is observed immediately
at this time. Neovascularization extending from the inner
retina into the vitreous begins at two days after the return
to room air, peaks on P17 [152], and is gradually regressed
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and spontaneously resolved by P25 [151]. A comprehensive
study was carried out in this model, in which mice at P18
were analyzed [153]. Morphologically, more gliotic Mu¨ller
cells and reactivated microglia can be observed. The total
retinal thickness was reduced in the midperipheral region,
while the IPL and the outer segment length were reduced in
the central andmidperipheral regions.The number of vessels
was also reduced in the IPL in the central region; and in
the deep plexus in the central and midperipheral regions.
Aberrant intravitreal neovascularization was observed across
all eccentricities. Retinal function was examined by ERG, in
which reductions in the amplitudes of a-wave, b-wave, OP3,
and OP4, and delayed b-wave implicit time were revealed.
Mouse OIR model showed a number of vascular, neuronal,
and glial changes in the retina; however, the spontaneous
regression of the neovascularization within a week confines
its application in therapeutic drug research.
Since DR can also be considered as an ischemic disorder
in the retina, retinal occlusion models, such as unilateral
ligation of pterygopalatine artery (PPA) and external carotid
artery (ECA) [154], branch retinal vein occlusion [155], and
elevating the intraocular pressure (IOP) [156], were also
applied in studies of vasculature abnormalities. In these
occlusion models, increased apoptotic cells, reduced thick-
ness of retinal cell layers, reduced a-wave, b-wave, and OPs
amplitudes of the ERG were evidenced. Nevertheless, the
acute induction of ischemia, particularly those followed by
reperfusion, to the retinal tissue makes these models less
appropriate for studying DR, in which chronic ischemia is
persistently involved.
Kimba (trVEGF029) is a transgenic mouse model of
neovascularization, as a result of transient overexpression
of human VEGF
165
in the rhodopsin-expressing cells with
which it peaks at P10 to P15 and declines at P20. Character-
ization studies have been carried out as early as at P7 [157].
At that time, reduced thickness of the RGC layer, INL, outer
nuclear layer (ONL), and the total retinal layer was observed.
By P28, such reduction was found in IPL, the outer segment,
and the total retinal layer. Microaneurysms, intraretinal
microvascular abnormalities, and capillary dropout were
evident by P28 [157]. Vascular leakage was also observed at
P28 [157], but it ceased at 9 weeks of age potentially due to the
absence of over-expression of VEGF [158]. Increased adhered
leukocytes were found in veins and capillaries, together with
increased acellular capillaries by 6 weeks of age. Topological
and fractal analysis of retinal vasculature showed that vessel-
covered area, vessel length, and crossing points in the 9-
week-old Kimba mice were reduced. Vessel tortuosity and
pericyte loss were also evident at this time point [158]. Varied
degrees of the pathogenesis were being reported, which were
separated into two groups based on the assessment of fundus
fluorescein angiography. The phenotypic observations of the
relatively severe group were presented in this review. Since
this transgenic mouse is not commercially available, it is not
a popular model in DR.
In order to generate an ideal mouse model to study DR, a
new mouse model of DR was created by crossing the Kimba
mice with the Ins2Akita mice, named Akimba [159]. These
mice inherit the key systemic diabetic phenotypes from their
parental strains, making it a unique model. At 8 weeks of
age, optical coherence tomography (OCT) showed uneven
thickness in the retina. Retinal edema and reduced photore-
ceptor layer thickness, togetherwith retinal detachment, were
observed. RGCs number and neural retinal thickness were
reduced by 24 weeks of age. Abnormal microvasculature,
including microaneurysms, capillary dropout, hemorrhage,
neovascularization, venous loops, vessel tortuosity, vessel
beading, vascular dilatation, and vascular leakage, were also
evident in mice of 8 weeks old, although the leakage stopped
by 20 weeks of age. The Akimba mouse model displays
a number of vascular changes; however, more complete
mechanistic studies are essential before its utilization in
therapeutic drug studies.
A summary of the earliest reported morphological and
functional lesions in different mouse models of DR is shown
in Table 2.
2.2. Rat Models of DR. Although rats have a slightly bigger
size than mice, they are still easy to handle with a low cost
of maintenance, making them to be another popular animal
frequently used in in vivo studies. The use of rats in DR study
is particularly common owing to a relatively larger tissue
size, with which functional assessment and morphological
and molecular analyses can be done. Similar to DR studies
in mice, three types of rat models were used; these include
pharmacological induction of hyperglycemia, spontaneous
diabetic rats, and models of angiogenesis without diabetes.
A summary of the morphological and functional lesions in
different rat models of DR is shown in Table 3.
2.2.1. Pharmacologically Induced Rat Models of DR. Similar
to mice, hyperglycemia can be induced in rats by injection of
STZ or alloxan or by ingestion of galactose.
Compared to mice, rats are more susceptible to the
toxicity of STZ; therefore, usually a much lower dosage of
STZ is used. In order to minimize the mortality, insulin com-
plementation may also be administered. Table 1 summarized
most of the induction method of STZ in the past 3 years
and served as a reference for the researchers to select the
most appropriate dosage, injection paradigm, and rats with
different genetic background for their studies. Amongst the
methods, a single dose of 60–65mg/kg of weight is the most
popular one. Variation of the retinal lesions was reported,
which can be explained by the genetic background. Indeed,
a comparative study showed a strain difference in the rate of
developing early DR symptoms in rats upon STZ challenge
[120]. After 8 months of hyperglycemia, Lewis rats displayed
accelerated degeneration of retinal capillaries and RGC loss,
whereas Wistar rats only showed the capillary degeneration
and Sprague-Dawley (SD) rats showed no morphological
defects to a significant level. Increased apoptotic cells were
detected throughout the retina as soon as 2 weeks after hyper-
glycemia [136]. After 1 month of hyperglycemia, the number
of astrocytes in the peripheral region was reduced; however,
the number of Mu¨ller cells and microglial cells is increased
[160, 161] with the accompany of microglial hypertrophy
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Table 1: Existing methods for induction of diabetes in rodents using STZ.
Compensation
of insulin Dosage Animal strain, age or weight
Onset of
hyperglycemia
Mouse
Single dose No 150mg/kg, i.p. C57Bl/6, 8–10wk old 6wk∗ [53]
No 150–180mg/kg, i.p. C57Bl/6, 10–12wk old 2wk [54]
No 180mg/kg, i.p. C57Bl/6, 10 wk old 1 day [41, 55]
No 200mg/kg, i.p.
C57Bl/6J, 10 wk old [56];
F1 hybrid (BALBc/129Sv ×
C57Bl/6J), 16 wk old [43]
3 days [56]
Yes 180mg/kg, i.p. C57Bl/6, 9–12wk old 1 wk [45, 48, 57, 58]
Yes 200mg/kg, i.p. C57Bl/6, 12 wk old 1 wk [47]
Multiple dose No 40mg/kg, i.p., for 5consecutive days C57Bl/6, 10 wk old 1 wk [59]
No 45mg/kg, i.p., for 5consecutive days C57Bl/6, 7-8 wk old 3 days [60]
No 50mg/kg, i.p., for 5consecutive days
C57Bl/6J, 4-5 wk old [61];
C57Bl/6J, 8-9 wk old
[46, 62];
C57Bl/6 [63]
1 wk [46]
No 55mg/kg, i.p., for 5consecutive days
C57Bl/6, 8–10wk old
[42, 64–66]
1 wk [42, 64, 66];
2 wk [65]
No 60mg/kg, i.p., for 3consecutive days
C57Bl/6, 5–8wk old
[34, 49, 50] 1 wk [34, 49, 50]
No 60mg/kg, i.p., for 5consecutive days
C57Bl/6, 6 wk old [40];
C57Bl/6J, 22 g [44];
C57Bl/6, 22 wk old [67]
1 wk [40, 44];
2 wk [67]
No 75mg/kg, i.p., for 3consecutive days C57Bl/6, 3–5 months old 5wk
∗ [68]
No 80mg/kg, i.p., for 3consecutive days C57Bl/6, 6–8wk 1wk [69]
No 80mg/kg, i.p., for 5consecutive days
F1 hybrid mice (FVB/N ×
C57Bl/6J), 10 wk old 1 wk [33]
No 100mg/kg, i.p., for 2consecutive days C57Bl/6J, 6–8wk old 1 wk [70]
Yes 50mg/kg, i.p., for 3alternate days C57Bl/6, 23–36 g 4wk
∗ [71]
Yes 50mg/kg, i.p., for 5consecutive days C57Bl/6 [72] Did not mentioned
Yes 60mg/kg, i.p., for 5consecutive days C57Bl/6 [73]; C57Bl/6J [38] 1-2 wk [38, 73]
Rat
Single dose No 30mg/kg, i.v. Wistar rats, 6 wk old 3wks [74]
No 45mg/kg, i.p.
Sprague-Dawley (SD) rats,
200–250 g [75, 76];
Wistar rats, 220–250 g [77]
1 day [77];
3 days [76];
1 wk [75]
No 45mg/kg, i.v. Wistar rats, 130–150 g 1 day [78]
No 50mg/kg, i.p. Brown Norway (BN) rats,8 wk old 2 days [79]
No 55mg/kg, i.p. Wistar rats, 8–12 wk old[80, 81] 3 days [80, 81]
Journal of Diabetes Research 7
Table 1: Continued.
Compensation
of insulin Dosage Animal strain, age or weight
Onset of
hyperglycemia
No 60mg/kg Lewis rats [82] Did not mentioned
No 60mg/kg, i.p.
BN rats, 200–250 g [83];
SD rats, 6–8wk old [84–91];
SD rats, 230–350 g [92, 93];
SD rats [94];
Wistar rats, 140–200 g
[95–97];
Wistar rats, 200–300 g
[98–100];
Long-Evens (LE) rats,
250–300 g [101]
1 day [83, 89];
2 days
[86–88, 91, 100];
3 days [84, 85, 92,
93, 97, 98]
1 wk [90, 96]
No 65mg/kg, i.p.
SD rats, 150–200 g [102–106];
SD rats, 240–275 g [107, 108];
Wistar rats, 8-9 wk old
[109–111]
1 day [106];
2 days
[107, 109–111];
3 days [102, 103];
1 wk [104, 105]
No 65mg/kg, i.v.
BN rats, 150–200 g [112];
LE rats, 150–200 g [112];
Wistar rats, 160–170 g
[113, 114]
3 days [112];
2 wk∗ [113, 114]
No 70mg/kg, i.p. SD rats, 8 wk old 12wk∗ [115]
No 75mg/kg, i.p. LE rats, 200–250 g 2 days [116]
No 80mg/kg, i.p. LE rats, 6–8wk old 1 wk [69]
Yes 45mg/kg, i.v. Wistar rats, 12 wk old 3 days [117]
Yes 50mg/kg, i.p. SD rats, 6 wk old 2wk [118]
Yes 55mg/kg, i.p. SD rats, 200 g 2-3 days [119]
Yes 55mg/kg
Lewis rats, 200 g [120, 121];
SD rats, 200 g [120];
Wistar rats, 200 g [120]
2wk∗ [120, 121]
Yes 60mg/kg, i.p.
Wistar rats, 129–170 g [58]
Wistar rats, 240–280 g∗∗
[122]
1 day [122];
1 wk [58]
Yes 65mg/kg, i.p. SD rats, 260 g 4wk∗ [123]
Yes 65mg/kg, i.v. SD rats, 200 g 4wk∗ [124]
Yes 70mg/kg, i.p. LE rats, 8 wk old 3 days [125, 126]
Yes∗∗ 80mg/kg, i.p. SD rats, 200 g 1 wk [127]
∗Indicates the earliest time point being mentioned by the authors.
∗∗Comparison between the insulin-treated versus untreated animals.
[160].The density of astrocyte was further reduced in the cen-
tral region, together with the reduction of astrocyte processes
in the peripheral region after 6 weeks of hyperglycemia [118].
Decreased total retinal thickness [163], as well as decreased
number of cells in the RGC layer [160], the ONL [163],
and the INL [160] was also reported. Regarding the vascular
changes, blood-retinal-barrier (BRB) breakdownwas evident
at 2 weeks of hyperglycemia [161, 163]. Increased adherent
leukocytes [164] and arterial or venous capillaries basement
membrane thickening [165] were observed at 8 weeks and
12 months after hyperglycemia, respectively. Retinal function
was affected from 2 weeks after the onset of hyperglycemia
as reflected by the ERG. Reduced b-wave [166], OPs [167],
and a-wave [166] amplitudes were progressively found at 2
weeks, 8 weeks, and 10 weeks of hyperglycemia. At around
the same time, the a-wave implicit time andOPswere delayed
[168]. Morphological and functional studies suggested that
STZ-induced diabetic rats only showed early DR symptoms,
which is comparable to those in STZ-induced mice.
The use of alloxan in DR studies is not very common
nowadays, and the existing morphological studies were
mainly focused on the vascular lesions. Neovascularization
was already observed from 2 months of induction of hyper-
glycemia starting from the midperiphery region and pro-
gressing to the whole retina after 9 months of hyperglycemia
[170]. Extravascular macrophage accumulation and capillary
endothelial cells swelling were also identified after 2 months
and 5 months of hyperglycemia, respectively [170]. By 8
months, increased cell death in the retinal microvasculature
was evident [171]. Acellular capillaries, basement membrane
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thickening, and pericyte loss were also reported upon 12
months of hyperglycemia [169]. Nevertheless, appearance of
the lesions varied between studies; it would be due to the
different time points selected by the authors or different
dosage of alloxan being injected. Reported lesions with the
“earliest onset” were listed in this review.
Similar to mice, DR can be studied in rats fed with
galactose, with the equivalent advantage of longer life span
[172, 198]. Studies showed increased retinalmicrovascular cell
death in 6 months after hyperglycemia [171]. Other vascular
lesions, such as acellular capillaries and basement membrane
thickening as well as pericyte loss, were observed after 12
months of feeding with galactose [169]. A long-term study
demonstrated cellular lesions, including gliosis and disrup-
tion of retinal layers, together with vascular abnormalities,
capillary dilation and microaneurysm formation in the inner
plexiform layer (IPL) and the INL, in rats fed with galactose
for 28 months [172]. Owing to the differences in galactose
concentration and time points selected by various studies, the
“earliest onsets” of the lesions were listed in this review.
2.2.2. Diabetic Rat Models Carrying Endogenous Mutation. A
number of rats with spontaneous onset of diabetes have been
identified. These include type 1 diabetic model: biobreeding
(BB) as well as type 2 diabetic model: Wistar Bonn/Kobori
(WBN/Kob) rats, Zucker diabetic fatty (ZDF) rats, Otsuka
Long-Evans Tokushima fatty (OLETF) rats, nonobese Goto-
Kakizaki (GK) rats, and nonobese spontaneously diabetic
Torii (SDT) rats.
Like NODmice, the BB rats spontaneously develop poly-
genic autoimmune type 1 diabetes, in which the pancreatic
𝛽-cells were selective destroyed [175, 199]. After 4 months
of hyperglycemia, absence of infolding and derangement of
the basal plasma lemma of the RPE were also observed [173].
The number of pericyte and the pericyte to endothelial cell
ratio were reduced [174, 175] after 8months of hyperglycemia.
Lesions associated with the retinal microvasculature, includ-
ing capillary dilation and basement membrane thickening,
were found from 2 months and 4 months of hyperglycemia,
respectively [175]. Microinfarctions with areas of nonper-
fusion were evident whereas no neovascularization was
detected up to 11 months [175]. Several inbred and outbred
lines, such as BB/Wor, BB/E, and BB/Ph, have been produced
and named based on the origin of the breeding colony. Since
genetic variations and potential differential phenotypes are
introduced, researchers should select the appropriate stain
carefully.
The WBN/Kob rats are a type 2 diabetes model owing
to endo-exocrine pancreatic insufficiency, and only male
offspring develop diabetic symptoms [200]. Retinal degen-
eration was already observed before the animal becomes
hyperglycemic at around 9 to 12 months of age. Thickness
of outer segments and ONL was reduced in WBN/Kob rats
at 5 months of age whereas high blood glucose was evident
in these rats at 10 months old [176]. About 2 months after
becoming hyperglycemic, these rats also showed reduction
in the visual cells, the OPL, and the total retinal layer
[176]. Vascular lesions were also identified, and capillaries
clustered into small tortuous knots after about 1 month
of hyperglycemia [177]. After 5 to 6 months of diabetes,
capillary basement membrane thickening [176], increased
capillary loop, and reduced number of capillary [177] were
also observed. After a prolonged hyperglycemia of 12months,
some rats showed increased proliferation of fibrovascular
element in the vitreous, intraretinal neovascularization, and
hyalinization of intraretinal vessels [178]. WBN/Kob rats,
which display the symptoms of the progressiveDR,may serve
as a model for testing therapeutic drug targeting angiogene-
sis. However, the early onset of neuronal degeneration (before
hyperglycemia commencement) suggests that the etiology of
retinal degeneration may not be the same as that in human;
therefore, further studies need to be carried out before this
can be used as a model for DR.
The ZDF rats are also a genetic model of type 2 diabetes.
They carry an inherited obesity gene mutation, which results
in impairment of glucose tolerance and insulin resistance
(http://www.criver.com/SiteCollectionDocuments/ZDF.pdf;
accessed on 19-Nov-2012). Excessive body weight gain
was observed in male ZDF rats in the first 6 months of
life, but the weight decrease to a level similar to the lean
controls afterwards [201]. Hyperglycemia starts at 6 to 7
weeks of age and maintains high throughout their life [180].
Retinopathological studies in these rats mainly focused
on the vasculature. Thickening of the capillary basement
membrane and increased capillary cell nuclear density
were reported in rats after 5 months of hyperglycemia
[180, 181]. Apoptosis of endothelial cells and pericytes
was higher in these rats compared to the lean controls,
together with an increased number of acellular capillaries
and pericyte ghosts upon 6 months of diabetes [179]. Retinal
functional analysis and long-term morphological studies of
the retinal neuronal and glial cells of these rats remain to be
elucidated.
Another type 2 diabetic rat model is OLETF rats; they
significantly gained more weight from 1 to 6 months of
age, but they lost weight from 9 to 10 months of age.
Elevated blood glucose was observed from 5 months of age
and it maintained high [182, 183]. After about 6 months
of hyperglycemia, despite no significant difference in the
number of acellular capillaries and pericyte ghosts [202],
OLETF rats with 9months of hyperglycemia showed reduced
ratio of pericyte area to the total capillary cross-sectional area
[183] and damaged endothelial cells [182]. By 14 months of
hyperglycemia, the INL and the photoreceptor layer became
thinner, accompanied with shortening of the RPE height
and poorly developed basal infoldings [182]. Relatively early
microvessel-related symptoms were reported in these rats, in
which leukocyte entrapment was evident in rats after 6 weeks
of hyperglycemia [184].Other abnormalities, including thick-
ening of capillary basement membrane, tortuosity, microa-
neurysms, loop formation in capillary, caliber irregularity
and narrowing of arteries, were also described in rats after
9 to 12 months of diabetes [182, 183, 185]. No hemorrhages,
emboli, and exudates were found in these rats up to 14months
of diabetes [182]. Moreover, ERG revealed that OLETF rats
fed with sucrose for 8 weeks had a prolonged peak latency of
∑OPs [203].The absence of acellular capillaries as well as the
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late onset of diabetes and the related symptoms diminished
the popularity of using this model to study DR.
The GK rat is a spontaneous model of non-insulin-
dependent diabetes without obesity.These rats are originated
from normal Wistar rats and they were selected via repeated
inbreeding exercise using glucose intolerance as a selection
index [186, 204]. Rats at 4–6 weeks of age develop hyper-
glycemia [186, 187]; they also showed reduction of retinal seg-
mental blood flows and prolonged retinal mean circulation
time after 1 month of hyperglycemia [186]. Increased BRB
permeability [187] and endothelial/pericyte ratio [186] were
also evident in 3 months and 7 months after the onset of
hyperglycemia. No significant differences were observed in
the retinal arterial and venous diameters [186]. Owing to the
limited publications on the retinopathology in the GK rats,
further characterizations on the non-vascular-related lesions
need to be performed.
The SDT rat, which is a substrain of the SD rat, is another
model of nonobese type 2 diabetes. Glucose intolerance
and impaired insulin secretion were demonstrated in the
male SDT rats at 14 weeks, followed by hyperglycemia
and glucosuria at 5 months of age. These rats showed a
sexual differentiation in the development of diabetes that
the cumulative incident is about 100% in males at 40 weeks
of age and only about 33% in females up to 65 weeks of
age [190, 205]. Retinal dysfunction was observed after 4
weeks of hyperglycemia, as evident by delayed peak latency
of the ∑OPs [189]. The amplitudes of a-wave, b-wave, and
∑OPs were significantly reduced with prolonged implicit
times at 24 weeks of hyperglycemia [193]. At the same
time, leukostasis [192] and the number of apoptotic cells in
the GCL and the INL [188] were increased in the retinas
of SDT rats. Vascular lesions, such as acellular capillaries
and pericyte loss, have been described by Kakehashi et al.
[206]. Advanced lesions, including leakage of fluorescein
around the optic disc as well as distortion of retina and
protruded optic disc, were also observed after 48 weeks
of hyperglycemia [189]. More importantly, a few studies
showed that proliferative DR can be detected in some of the
aged SDT rats, which have been exposed to hyperglycemia
for more than 48 weeks [190, 191, 205, 206]. The reported
symptoms include retinal hemorrhages, tortuous vessels,
capillary nonperfusion, neovascularization, and tractional
retinal detachment with fibrous proliferation. Amongst the
diabetic rat models mentioned in this review, the SDT rat is
the only one that shows severe ocular complications similar
to those seen in human. Although some commonphenotypes
in human DR, such as microaneurysms and development of
avascular area, are rare in this model, this is a unique model
to study proliferative DR [205, 207].
2.2.3. Rat Models for Angiogenesis Study. Similar to the
mouse models for studying angiogenesis, OIR and occlusion
models were also applicable to rats. Owing to the relevance
of ischemic-induced neovascularization, we will focus on the
OIR in this section.
The basic principle of OIR in rats is very similar to that
in mice, which involves the induction of neurovasculariza-
tion in nondiabetic animals. Different from the “standard”
protocol of OIR in mice, several paradigms with varied
oxygen concentrations and duration of the exposure period
have been applied in rats. In brief, the newborn pups are
exposed in alternative hyperoxia-hypoxia cycles for 11 to 14
days and then returned to room air [194, 195, 208–210].
Peripheral astrocyte degeneration was observed soon after
the rats were exposed to room air [195]. At P18, the number
of astrocyte was reduced almost throughout the whole retina
[195] with prominentMu¨ller cell reactivity in the regions that
are devoid of intraretinal blood vessels [194]. Reduction of
thickness in the INL, the IPL, and the total retinal layers was
evident [194]; the outer segment layer also became thinner
and disorganized [196]. While the number of pericytes was
comparable to the room air control, the pericyte-endothelial
interactions were impaired [195]. Intravitreal neovasculariza-
tion, incomplete development of the outer vascular plexus
and extension of the abnormal endothelial “tufts” toward
the vitreous were observed in the OIR rats [195]. Functional
lesions were also studied using ERG, in which the a- and
b-wave amplitudes were reduced [197]. This model is useful
in therapeutic drug screening or in the study of the mech-
anisms in angiogenesis, yet special equipments are required.
Moreover, strain-dependent difference in the degree of retinal
vascularization and abnormalities in vascular morphology
have been reported [208]. The albino SD, the pigmented
Dark Agouti, and Hooded Wister rats were more prone to
the hyperoxia-hypoxia challenge, and they showed severe
vascular attenuation following the oxygen exposure as well as
severe vascular pathologies when compared to other strains.
In summary, rodents are very popularmodels to study the
pathogenesis and examine the efficiency of therapeutic drugs
of DR in laboratories.They have the advantage of being small
in size which allows easier handling; however, this alsomakes
in vivo examinations, such as fundus photography, fundus
fluorescein angiography, and optical coherence tomography,
difficult. Despite the lack of proliferative DR symptoms
as described in most of the models mentioned above,
researchers also focus on other animals in order to obtain
the most representative model of DR, which ideally displays
the comparable DR symptoms as seen in human patients.
Higher mammals not only can serve as a platform for easier
examinations but also allow easier treatment particularly
those involving sophisticated surgical procedures. In these
animals, sampling of body fluid, for example, vitreous and
blood, can also be performed routinely.
2.3. Rabbit Models of DR. Similar approaches have been
applied to rabbits to induce DR; these include pharmacologi-
cally induced and dietary-induced diabetic models as well as
VEGF-induced angiogenesis in the retina without affecting
the blood glucose level.
2.3.1. Pharmacologically Induced Rabbit Models of DR.
Hyperglycemia can be induced in rabbit by STZ, although
this method is not very frequently used. A study showed
that intravenous injection of STZ (100mg/kg) in rabbits can
elevate their blood glucose level [211]. Fundus examination
was done after 19 weeks of hyperglycemia and all eyes showed
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certain degree of retinopathy, of which 50% showed prolif-
erant retinopathy; 40% showed serious vasculopathy with
serious retinal and preretinal hemorrhages, vascular lesions,
hemovitreous and venous thrombosis; and the remaining 10%
showed moderate vasculopathy with hard or soft exudates
and widespread hemorrhages. Variation in the extent of the
retinopathogenesis limits the use of this model.
2.3.2. Diet-Induced Rabbit Models of DR. Early DR can be
found in rabbit models of diet-induced impaired glucose
tolerance plus hyperlipidaemia [212]. Rabbits were fed with
standard chow with 10% lard, 40% sucrose, and 0.1–0.5%
cholesterol for a period of 24 weeks. The blood glucose level
slightly elevated in the animals after feeding with 12 weeks
of the special diet, and they became hyperglycemic by the
end of the study period. Histological findings suggested that
increased microaneurysms and hyperfluorescent dots were
already present before the rabbit becomes hyperglycemic,
while those pathological symptoms further progressed with
prolonged feeding. Although this model mimics the natural
development of type 2 diabetes in human, the drawback is the
slow progression of DR symptoms.
2.3.3. Rabbit Models for Angiogenesis Study. In brief, a
polymeric pellet containing human recombinant VEGF was
implanted into the vitreous cavity of the rabbit [213]. After
7 days of implementation, increased dilation and tortuosity
of retinal vessels were observed. During 14 to 21 days after
implementation, fluorescein angiography further showed
profuse leakage of dye, together with the presence of numer-
ous small tortuous blood vessels, suggesting induction of
neovascularization. However, such vascular changes stopped
afterwards and neovascularization almost totally regressed
after 35 days of implementation. The authors suggested that
the regression of vessels may be due to depletion of the
VEGF, implying that choosing the experimental endpoint
is crucial when screening therapeutic agents in this model.
Therefore, another group generated a similarmodel, in which
human recombinant basic fibroblast growth factor (bFGF)
was also incorporated into the polymeric pellet besides the
human recombinant VEGF [214]. In this model, similar
retinopathologies were observed but they only required
approximately half of the time to develop when compared
with the VEGF-induced model previously described. In
addition, hemorrhage from the new vessels and even total
traction retinal detachment were also observed. Moreover,
differential retinal angiogenic response to VEGF/bFGF was
reported in different rabbit strains, where Dutch belt rabbits
are more susceptible than the NZW/Black satin cross rabbit
[215].
It is evident that vascular retinopathy could be observed
in the rabbit models mentioned above; however, researchers
should be aware of the fact that retinal vasculature in the
rabbit differs from those in other species. In rabbit, the optic
artery branches into major blood vessels in a bidirectional
horizontal manner; they further arborized into capillaries,
forming a ring-like network. Moreover, the visual streak of
rabbit is located below this region; functional defects may not
be able to be detected if the lesion site is in the medullary
ray where the blood vessels are. As compared with other
animals, such vascular system is only present in a small
area of the retina in rabbit; therefore, the global deleterious
contributions by the vessels may be underestimated. On
the other hand, if researchers aim to study the vessel-to-
cell interaction at a molecular level, this model provides an
alternative choice with an additional advantage of a bigger
eyeball size than rodents.Therefore,more precise and delicate
experiments can be performed, but the problem of limited
housing space needs to be attended to.
2.4. Cat Model of DR. The majority of the DR studies in
cats are induced by pancreatectomy with or without alloxan
injection.The animal will become hyperglycemic 1 to 2 weeks
after the surgery [216–218]. Capillary basement membrane
thickening was first described from 3 months of pancrea-
tectomy, where no change was observed in the number of
endothelial cells and pericytes as well as the contacts between
endothelial cells and pericytes up to 10 months [218]. A case
report showed that microaneurysm was first observed in one
eye in a diabetic cat after 5 years of pancreatectomy; and
by 6.5 years, both eyes showed microaneurysms and small
intraretinal hemorrhages in the area centralis [216]. Region
of capillary nonperfusion and intraretinal microvascular
abnormalities (IRMA) were also evident from 7.5 years. At
8.5 years, presence of small foci of neovascularization was
suggested. Cotton-wool spots, venous beading, extensive
preretinal neovascularization, ormicrovascular changes were
not found in the peripheral retina. On the other hand,
another study showed that only one out of two experimental
diabetic cats showed microaneurysms, but not hemorrhages
or area of nonperfusion, after 7 years of pancreatectomy,
while the other diabetic cat did not show anymicroaneurysm
or hemorrhage in the retina [217]. Cats only showed mild
cataracts upon diabetes, thereby allowing visualization of the
fundus angiography and ERG. However, the studies of DR
in cat are very limited and the described phenotypes are less
consistent. A long follow-up period for the development of
retinal pathology and lack of reagents in molecular studies
may be the drawbacks for using this animal model.
2.5. Dog Model of DR. Attempts of using dogs for studying
DR have also been made, in which most of them are
about inducible hyperglycemia either by injection of STZ or
alloxan or feeding the animals with galactose. It has been
suggested that galactose-fed dog is the animal model that
shares the retinal lesions morphologically and clinically as
those developed in human diabetic patients [219].
2.5.1. Pharmacologically Induced Dog Models of DR. Induc-
tion of diabetes in dogs by intravenous injection of STZ
and alloxan resulted in basement membrane thickening in
3 years of injection, and it was recognized in some vessels
from the first year [220]. Loss of pericytes and smoothmuscle
cells was observed in the retinal arterioles from 4 years of
postinjection; no microaneurysm was noted towards the end
of this 5-year study. Moreover, a comparative study showed
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that increasedmicroaneurysms, acellular capillaries, pericyte
ghosts, endothelial cells to pericytes ratio, and basement
membrane thickening were evident in the dogs after 5 years
of galactosemia than those of alloxan-induced diabetes [221].
In the galactose-induced DR model, experimental dogs
were continuously fed with normal diet supplemented with
30% galactose. Cellular lesions such as presence of pericyte
ghosts and uneven distribution of endothelial cells were
observed in retina of dogs after feeding with galactose for
19 and 24 months, respectively, followed by the formation
of microaneurysms [222, 223]. Dot and blot hemorrhages
were found from 33 months, which became more confluent,
progressing to the preretinal and intravitreal regions after
66 months of feeding [222]. Nonperfusion was evident in
dogs from 37 months of feeding [223, 224], and the area
was broadened with time [222]. After 36-month feeding
of galactose, acellular capillaries and endothelial cells to
pericytes ratio were increased [225]. Other vascular lesions,
such as abnormalities in intraretinal microvessels, occlusion
of arterioles, presence of large arteriovenous shunts, and
node formation on arterial and arteriolar walls, were also
reported after feeding for about 5 years. At about the same
time, presence of soft exudates and gliosis in the nerve fiber
layer was reported [222]. Further advanced retinopathy of
neovascularization was described in dogs being galactose fed
for 68 to 84 months [222, 224]. It has been suggested that
the onset of DR symptoms is age dependent in galactose-fed
dogs; younger animals developDR symptoms earlier than the
older ones [225]. This may explain the variation of the onsets
of the lesions mentioned above.
The biggest advantage of using dogs as a model is that
they develop similar retinal morphological lesions as com-
pared with human. Routine in vivo vasculature assessments,
however, were impeded owing to the spontaneous diabetic
cataract, particularly in the galactose-fed model; additional
lensectomy is necessary [219, 223, 224]. Moreover, high
maintenance cost, long-term follow-up period, and lack of
molecular reagents, such as antibodies, make this model less
commonly used for studying DR.
2.6. Swine Model of DR. Pig eye has become a useful tool in
eye research because of its close similarities in the size as well
as the basic retinal structure and vasculature to the human eye
[226]. A number of models have been generated in order to
study the retinopathy in swine upon diabetes, which include
alloxan- and STZ-induced type 1 diabetic models. There
is also a recently developed model of proliferative vitreo-
retinopathy that involved surgical procedures and intravitreal
injection of retinal pigment epithelial (RPE) cells.
2.6.1. Pharmacologically Induced Swine Models of DR. There
are only limited reports on the retinal morphology of the
chemically induced diabetic pigs. Instead, researchers make
use of the large amount of specific retinal cells and vitreous
available in the pig eyes for in vitro experiments [227,
228]. Nevertheless, reactivation of Mu¨ller cells was evident
from the increased GFAP immunoreactivity from the ONL
extending to the outer limiting membrane [227] in 2 to 3
months after onset of alloxan-induced diabetes. At around 4
months of hyperglycemia, pericyte degeneration in parallel to
reduced the total number of BRB capillaries and capillary col-
lapse were also observed [229]. Retinal vascular lesions, such
as basement membrane thickening [230, 231] and rarefaction
[231], were reported in pigs after 18 weeks of STZ-induced
diabetes. Development of hyperglycemic cataract was also
reported in this animal after 32 weeks of hyperglycemia that
constrain the visualization of the vasculatures, such as fundus
angiography [231].
2.6.2. Swine Model for Angiogenesis Study. Recently, a new
swine model of proliferative vitreoretinopathy has been
described [232]. In brief, vitreal and retinal detachments were
initially induced by vitrectomy and injection of subretinal
fluid, respectively, prior to injection of cultured RPE cells into
the vitreous cavity. Formation of contractile membranes on
the inner retinal surface as well as localized tractional retinal
detachments was evident and maintained after 14 days of
induction while the retina reattached in the control animals
at 3 days after the surgery. Further characterization of this
model needs to be carried out before its use in therapeutic
drug screening.
Although pig is a valuable model for disease study
in human, high maintenance cost, requirement of special
housing facilities, and lack of biochemical reagents make this
model less commonly being used.
2.7. Monkey Model of DR. Monkey, a nonhuman primate, is
considered to be a potentialmodel in eye research owing to its
structural similarity to human and, in particular, the presence
of macula. The studies of DR in monkey can be divided into
3 groups: type 1 diabetic model, type 2 diabetic model, and
model of VEGF-induced neovascularization.
2.7.1. Type 1 Diabetic Monkey Models. In an attempt to
produce DR in monkeys, monkeys with type 1 diabetes that
developed spontaneously as well as that resulted from total
pancreatectomy or STZ injection were being used [233].
Unexpectedly, 37 out of 39 of thesemonkeys did not show any
significant DRwithin 5 years of hyperglycemia. Animals with
hyperglycemia of 6 to 15 years only showed mild disruption
of the blood-retinal barrier. On the other hand, sponta-
neous or pharmacological induction of hypertension in the
hyperglycemic monkeys, either by STZ injection or with
spontaneous diabetes, resulted in ischemic retinopathies,
such as cotton-wool spots which were found in the peripap-
illary region, microaneurysms, capillary dropout, capillary
dilatation, focal intraretinal capillary leakage spots, arteriolar
and venular occlusions, and atrophic macula, between 6 and
15 years of diabetes.The authors suggested that the fluctuating
blood glucose levels and systemic blood pressure, but not
hyperglycemic alone, play a role in the pathogenesis of DR.
2.7.2. Type 2 Diabetic Monkey Models. DR studies have also
been carried out inmonkeys that spontaneously develop type
2 diabetes. While moderate retinal lesions can be identified
in a case of monkey with 3 years of diabetic history, no
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detectable retinopathywas reported in amonkeywith 15 years
of diabetes [234]. The presence of these lesions was variable
in individual animals, making it hard to deduce the precise
onset of symptoms based on the diabetic duration. Among
those showing retinopathies, cotton-wool spots, intraretinal
hemorrhages, and nonperfused areas were the early observa-
tions. Progressive lesions, such as growing nonperfused area,
which are associated with the formation small IRMAs and
microaneurysms, as well asmacular edemawere also evident.
Similar observations were also reported in another case study
in which the subject is a monkey with at least 5 years of
diabetes [235].The authors havementioned other histological
abnormalities, including reduction of the thickness of the
ONL and the inner and outer segments of the photoreceptor
layers. Functional lesions were suggested by a loss in the
amplitudes in the multifocal ERG, and they were virtually
correlated to the nonperfused areas. Progressive reduction of
amplitudes and delayed a-waves were also observed in the
dark-adapted Ganzfeld ERG, suggesting a loss of function in
the both inner and outer retina and reduced sensitivity in
the photoreceptors, respectively. Moreover, it is reported that
the occurrence of retinopathy is correlated with hypertension
[234], which is coincidently similar to the descriptions in the
type 1 diabetic monkey model.
2.7.3. Monkey Models for Angiogenesis Study. VEGF-induced
proliferative retinopathy has also been carried out in non-
human primates [213]. In brief, a pellet containing human
recombinant VEGF was implanted into the vitreous cavity
of the animal. At 2 weeks after the implementation, severe
BRB breakdown was noted. Retinal vascular dilation and tor-
tuosity were further observed in 3 weeks. The abnormalities
peaked at 3 weeks and regressed afterwards. Neovasculariza-
tion was not detected in this model.
There are many limitations in using monkeys in DR stud-
ies. Apart from the variations in the onset of morphological
abnormalities and the absence of advanced retinopathies,
low birth rate, high cost, long duration of study, and the
heightened ethical concern make this model unfeasible for
the purpose of drug screening.
2.8. Zebrafish Model of DR. Despite the enormous ethical
concern in the laboratory use of the mammals mentioned
above, in particular the primates, the recent emergence
of zebrafish can resolve this complication. Zebrafish is
extensively used in the study of visual development and
impairments owing to its similarity to those seen in human
[236]. The distinctive pattern of the mammalian retinal cell
layers, ranging from ganglion cell layer to retinal pigment
epithelium, is observed in zebrafish [236]. The retinal vas-
culature is rather complex in adult zebrafish [237]. Blood
supply to the retina is supported by the optic artery, which
branches into four to nine major blood vessels. These vessels
further arborize into smaller vessels towards the peripheral
of the retina where anastomosis between the neighboring
capillaries is present. This radial vascular network covers the
entirely inner surface retinawith direct contact with theGCL.
Oxygen-deprived blood is collected in the circumferential
vein surrounding the retina where the cilliary marginal zone
is. DR can be studied in zebrafish via direct elevation of
glucose in the surrounding as well as angiogenesis without
the involvement of glucose.
2.8.1. Glucose-Induced Diabetic Model of DR. In brief,
zebrafish was exposed to freshwater with alternation between
2% and 0% glucose in every 24 hours for 30 days [238].
Hyperglycemia can be achieved in the animal in 1 day of
immersion in the 2% glucose freshwater and maintained for
at least 30 days with repeated hyperglycemic spikes every
time after the removal from the glucose-freshwater. After 28
days of persistent hyperglycemia, the thickness of the IPL
was significantly decreased, and yet no other abnormality has
been observed [238]. The mechanism of glucose uptake in
zebrafish is regulated by osmoregulation, in which influx of
water, together with glucose, goes into their body as a result
of high internal salt concentration. It has been reported that
teleosts also have endocrine islet tissue containing hormone-
producing cells which converge in the fish body, and the
secretory teleost insulin is functional and is homologous to
the human insulin [239]. This further validates the potential
use of glucose-induced diabetic zebrafish in studying the
retinopathy. Yet, morphological studies associated with the
retinal vessels remained to be performed.
2.8.2. ZebrafishModels forAngiogenesis Study. Twomodels to
study angiogenesis in zebrafish are described below, namely,
environmentally and transgenic-induced models.
Retinal neovascularization can be achieved by keeping
the zebrafish in hypoxic aquaria where the air saturation
is gradually reduced to 10% (820 bbp) over a course of
48 to 72 hours and maintained for 12 days [240, 241]. In
these studies, fli-EGFP-Tg zebrafish, which is a transgenic
line that overexpresses EGFP in the vascular endothelium,
was used for easy visualizing and imaging of the blood
vessels. After 12 days of hypoxic challenge, neovascularization
was observed in the retina evident by increased number of
branch points, sprouts, and vascular area as well as reduced
intercapillary distance [240]. This model can be useful for
studying the development of angiogenesis or possibly for
screening antiangiogenic pharmacological agents.
Retinal angiogenesis can also be induced in zebrafish
via transgenic approach. Zebrafish carrying vhl−/− mutation
displays an upregulation of hypoxia-inducible factor, which
in turns triggers VEGF production and expression of the
VEGF receptors [242]. By 5.75 days after fertilization (dpf),
increased hyaloids and choroidal vascular networks were
observed, followed by vascular leakage at 7.25 dpf. Excessive
blood vessels were evident in the IPL, together with severe
macular edema and retinal detachment at 7.5 dpf. However,
this model is not commercially available, which limits its
use in the field even though severe neovascularization and
proliferative retinopathy are observed.
Zebrafish is very small in size; therefore, its maintenance
is simple, convenient, and inexpensive. They have a short
life span and a large breeding size, which in turn allow a
shorter experimental turnover time. Moreover, a number
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of studies showed that genes of interest can be specifically
induced, deleted, or overexpressed in zebrafish, allowing
mechanistic studies of diseases [243]. As a consequence,
researchers have developed certain zebrafish models in order
to study DR, including glucose-induced diabetic model and
models specifically of angiogenesis. However, the retinal cells
layers differ in thickness and thereby the number of cells,
the findings may under- or overestimate the contribution
of a specific cell type in regard to the pathogenesis of DR.
In terms of the vasculature in zebrafish, the growth of the
tertiary plexus of blood vessels in the INL is absent and the
venous system is different from those in human. Therefore,
researchers should be aware that using zebrafish may lead
to potential discrepancy in cellular and vascular aspects and
may not truly reflect the pathological development of DR in
patients. Moreover, owing to the limited supply of tissue from
a single animal, skillful techniques and a large quantity of
eyeballs are required in dissection and formolecular analysis.
A summary of the temporal morphological and func-
tional lesions of the animal models, other than rodents,
described above is shown in Table 4. Table 5 displays general
comparisons of the use of different animals in studying
DR.
3. Conclusions
Animal models are very important in understanding the
pathogenesis of diseases in human, defining novel therapeu-
tic targets as well as screening of novel therapeutic drugs.
In this review, a number of animal models of DR have
been described and compared, ranging from different species
to different induction methods of diabetes or angiogenesis,
together with their corresponding temporal morphological
and functional lesions. Up to date, there is no single model
which can mimic the development of DR as in human, that
is, from the very early cellular and vascular abnormalities to
the proliferative stage, and subsequently retinal detachment,
as a result of prolonged hyperglycemia. Rodents have been
extensively used in DR studies owing to their small size and
the ability to develop retinopathies within a relatively short
period of time. The availability of a collection of transgenic
mice further aids in elucidating the role of target molecules
in DR. Since the STZ-induced diabetic rodents are the most
frequently used models in studying the associated retinopa-
thy, we have summarized the administration dosage and
paradigm published in the recent years as a reference to other
researchers. Nevertheless, a majority of the diabetic rodent
models only demonstrated the early symptoms of DR, which
restricts their applications in mechanistic studies and drugs
screening targeting the early progression ofDR. Somehigher-
order animals showed relatively advanced retinopathies, such
as neovascularization, upon induction of diabetes, yet they
still cannot imitate the later stage of DR as seen in human.
Moreover, high maintenance cost, long duration of study,
and lack of molecular reagents, such as antibodies, as well as
ethical concern further limit their use in studies. Zebrafish is
another model that emerged recently in studies of DR; how-
ever, further characterization needs to be done. The presence
of neovascularization is controversial in some animalmodels;
such variationmay come from animals of different strain and
age, individual variation, and/or even the detection methods.
Therefore, we suggested that researchers should have a bigger
sample size, use at least two detection methods, such as
fluorescence angiography, immunohistochemical staining of
blood vesselmarker on retinal flatmounts or cross-sections in
combination withmolecular analysis, in order to have amore
convincing claim. Furthermore, overexposure of the fluores-
cence staining and “cleanness” of the section, particularly in
the flat mounts, are other issues that researchers should be
aware of. Although neovascularization can be observed in
animals overexpressing VEGF, either via transgenic approach
or direct introduction, the development of neovasculariza-
tion is not caused by prolonged hyperglycemia. Therefore,
using these models in studies of the etiology of the disease or
the development of preretinal neovascularization should be
avoided. Another approach for induction of neovasculariza-
tion is by hypoxic challenge in rodents; however, regression
was reported within a few days, whichmay limit the duration
of the drug treatment versus the formation of new vessels. As
outlined in this review, individual model of DR has different
strengths and weaknesses; careful consideration should be
made in choosing appropriate models to address the research
questions.
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